Bioethics Stock Net Income
| BOTH Stock | USD 0.01 0.00 0.00% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Bioethics' long-term financial health and intrinsic value.
Bioethics |
Bioethics Company Net Income Analysis
Bioethics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Bioethics Net Income | (107.18 K) |
Most of Bioethics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bioethics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Bioethics reported net income of (107,183). This is 100.01% lower than that of the Financial Services sector and significantly lower than that of the Shell Companies industry. The net income for all United States stocks is 100.02% higher than that of the company.
Bioethics Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bioethics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Bioethics could also be used in its relative valuation, which is a method of valuing Bioethics by comparing valuation metrics of similar companies.Bioethics is currently under evaluation in net income category among its peers.
Bioethics Fundamentals
| Return On Asset | -56.39 | |||
| Current Valuation | 647.72 K | |||
| Shares Outstanding | 1.14 M | |||
| Shares Owned By Insiders | 88.53 % | |||
| Price To Book | 2,021 X | |||
| EBITDA | (59.14 K) | |||
| Net Income | (107.18 K) | |||
| Cash And Equivalents | 554 | |||
| Total Debt | 398.53 K | |||
| Book Value Per Share | (0.58) X | |||
| Cash Flow From Operations | (27.48 K) | |||
| Earnings Per Share | (0.09) X | |||
| Beta | 0.53 | |||
| Market Capitalization | 295.15 K | |||
| Total Asset | 734 | |||
| Net Asset | 734 |
About Bioethics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bioethics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bioethics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bioethics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Bioethics Pink Sheet
Bioethics financial ratios help investors to determine whether Bioethics Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bioethics with respect to the benefits of owning Bioethics security.